CXCL13 and melanoma: The over-expression of COL11A1, CXCL13, PTPRF and SHC4 in our melanoma cell lines and primary and metastatic tissue, and their potential association with MAPK pathways suggests they could be specific biomarkers for melanoma and so potential therapeutic targets.